Structural features of coronavirus SARS-CoV-2 spike protein: Targets for vaccination

Publication date: 15 September 2020Source: Life Sciences, Volume 257Author(s): Ariane Sternberg, Cord Naujokat
Source: Life Sciences - Category: Biology Source Type: research

Related Links:

Drug Res (Stuttg) DOI: 10.1055/a-1217-2397The current outbreak of novel Coronavirus Disease-2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a major pandemic situation and a catastrophe for humans. COVID-19 is a severe infectious disease particularly of the respiratory system characterized by fatal complications such as severe acute respiratory distress syndrome (SARS), pneumonia, cardiac arrhythmia, kidney failure/ multiple organ failure and even death. Since its discovery, the SARS-CoV-2 has spread across 213 countries or territories, causing mor...
Source: Drug Research - Category: Drugs & Pharmacology Authors: Tags: Review Source Type: research
Approximately 17 years after the severe acute respiratory syndrome coronavirus (SARS-CoV) epidemic, the world is currently facing the COVID-19 pandemic caused by SARS corona virus 2 (SARS-CoV-2). According to the most optimistic projections, it will take more than a year to develop a vaccine, so the best short-term strategy may lie in identifying virus-specific targets for small molecule–based interventions. All coronaviruses utilize a molecular mechanism called programmed −1 ribosomal frameshift (−1 PRF) to control the relative expression of their proteins. Previous analyses of SARS-CoV have revealed tha...
Source: Journal of Biological Chemistry - Category: Chemistry Authors: Tags: Accelerated Communications Source Type: research
The U.S. domestic response to the COVID-19 pandemic thus far has been “weak,” Bill Gates believes. The Bill and Melinda Gates Foundation co-chair and Microsoft co-founder told TIME senior health correspondent Alice Park during a TIME100 Talks discussion on Thursday that he’d give the U.S.’s COVID-19 response, “on a relative and absolute basis, not a passing grade.” But, he added, the U.S.’s funding for vaccine and therapeutic research “has been the best in the world,” so if it coordinates to share resources globally, the U.S. could “potentially score the highest&...
Source: TIME: Health - Category: Consumer Health News Authors: Tags: Uncategorized COVID-19 News Desk TIME100 Talks Source Type: news
By MICHEL ACCAD, MD With cases of COVID-19 either disappeared or rapidly diminishing from places like Wuhan, Italy, New York, and Sweden, many voices are speculating that herd immunity may have been reached in those areas and that it may be at hand in the remaining parts of the world that are still struggling with the pandemic.  Lockdowns should end—or may not have been needed to begin with, they conclude. Adding plausibility to their speculation is the discovery of biological evidence suggesting that prior exposure to other coronaviruses may confer some degree of immunity against SARS-CoV...
Source: The Health Care Blog - Category: Consumer Health News Authors: Tags: COVID-19 Health Policy immunity MICHEL ACCAD Pandemic Source Type: blogs
NEW BRUNSWICK, N.J., July 30, 2020 – Johnson &Johnson (NYSE: JNJ) (the Company) today announced that its lead vaccine candidate protected against infection with SARS-CoV-2, the virus that causes COVID-19, in pre-clinical studies. The data, published in Nature, show the Company’s investigational adenovirus serotype 26 (Ad26) vector-based vaccine elicited a robust immune response as demonstrated by “neutralizing antibodies,” successfully preventing subsequent infection and providing complete or near-complete protection in the lungs from the virus in non-human primates (NHPs) in the pre-clinical st...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Our Company Source Type: news
Abstract Virus onslaughts continue to spread fear and cause rampage across the world every now and then. The twenty first century is yet again witnessing a gross global pandemic, Coronavirus Disease 2019 (COVID-19) caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Globally no vaccines or drug specific to COVID-19 is available. Corona viruses have been in mutual relationship with humans and other hosts over many decades though aggressive zoonotic strains have caused havoc. Zoonotic emergent corona viruses prior to SARS-COV-2 included severe acute respiratory syndrome coronavirus (SARS-CoV) and...
Source: European Journal of Pharmacology - Category: Drugs & Pharmacology Authors: Tags: Eur J Pharmacol Source Type: research
Abstract The world is currently facing the COVID-19 pandemic, for which mild symptoms include fever and dry cough. In severe cases, it could lead to pneumonia and ultimately death in some instances. Moreover, the causative pathogen is highly contagious and there are no drugs or vaccines for it yet. The pathogen, SARS-CoV-2, is one of the human coronaviruses which was identified to infect humans first in December 2019. SARS-CoV-2 shares evolutionary relationship to other highly pathogenic viruses such as Severe Acute Respiratory Syndrome (SARS) and Middle East respiratory syndrome (MERS). We have exploited this sim...
Source: Journal of Biosciences - Category: Biomedical Science Authors: Tags: J Biosci Source Type: research
ml;nch J, Müller JA Abstract SARS-CoV-2 is a novel pandemic coronavirus that caused a global health and economic crisis. The development of efficient drugs and vaccines against COVID-19 requires detailed knowledge about SARS-CoV-2 biology. Several techniques to detect SARS-CoV-2 infection have been established, mainly based on counting infected cells by staining plaques or foci, or by quantifying the viral genome by PCR. These methods are laborious, time-consuming and expensive and therefore not suitable for a high sample throughput or rapid diagnostics. We here report a novel enzyme-based immunodetection ass...
Source: Antiviral Research - Category: Virology Authors: Tags: Antiviral Res Source Type: research
Two doses of an experimental vaccine to prevent coronavirus disease 2019 (COVID-19) induced robust immune responses and rapidly controlled the coronavirus in the upper and lower airways of rhesus macaques exposed to SARS-CoV-2, report scientists from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. SARS-CoV-2 is the virus that causes COVID-19.
Source: World Pharma News - Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news
“There’s No Going Back to ‘Normal’”, crudely proclaims the headline of a June piece from The Atlantic. “The Terrible Consequences of Australia’s Uber-Bushfires” reads a recent Wired article. One of our own April articles was titled “Will Medical Workers Deal With PTSD After COVID-19?”. If it wasn’t clear, an article published earlier this year in The Conversation rightly asks: “Are we living in a dystopia?”.  Indeed, what was once relegated to the fertile minds of fiction novelists has become daily occurrences. Many are drawing similariti...
Source: The Medical Futurist - Category: Information Technology Authors: Tags: Artificial Intelligence Future of Medicine Future of Pharma Science Fiction Security & Privacy Telemedicine & Smartphones Virtual Reality black mirror dystopia coronavirus covid19 jumanji Death Stranding video games bushfires Source Type: blogs
More News: Biology | Coronavirus | COVID-19 | SARS | Vaccines